Navigation Links
LX4211 for Diabetes Shown to Reduce Fasting and Post-Prandial Blood Sugar in Healthy Subjects
Date:9/13/2011

f clinical trials, and the potential therapeutic and commercial potential, of LX4211. This press release also contains forward-looking statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct clinical development of LX4211 and preclinical and clinical development of its other potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Unless specifically indicated otherwise, results reported as trends were not statistically significant. Information identifying such important factors is contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2010, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
2. Phase 2 Trial of LX4211 Demonstrates Significant and Rapid Improvements in Multiple Parameters in Type 2 Diabetic Patients
3. Lexicon Presents Data Describing LX4211 Positive Phase 2 Clinical Results and Novel Mechanism of Action for Type 2 Diabetes
4. Lexicon Announces Positive Results from New Clinical Study of LX4211 in Type 2 Diabetes Patients
5. Lexicon Presents LX4211 Mechanism of Action Data at American Diabetes Association Meeting and Announces Commencement of Phase 2b Clinical Trial in Type 2 Diabetes
6. Lexicon Presents LX4211 Clinical Data at European Association for the Study of Diabetes Annual Meeting
7. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
8. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
9. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
10. Isis Initiates Phase 1 Study of ISIS 325568 Targeting Glucagon Receptor to Treat Type 2 Diabetes
11. Diabetes Research Institute Invention Promotes Growth of Stem Cells into Insulin-Producing Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... Leading events organizer UBM Live announces that CPhI ... São Paulo, Brazil from 5 th ... co-locate with Food Ingredients South America (FiSA), creating ... pharmaceutical industry.      (Logo: http://photos.prnewswire.com/prnh/20130723/629764-a) Three ... exploring the South America market as ...
(Date:7/24/2014)... CITY, Calif. , July 24, 2014   ... specialty pharmaceutical company focused on the development and commercialization ... breakthrough pain, today confirmed the PDUFA date for Zalviso ... learned that a rumor circulated online stating the Food ... July 24, 2014 there has been no notification to ...
(Date:7/24/2014)... MARSEILLE , Frankreich, July 24, ... , Weltweite Exklusivlizenz der Universität ... von Tests auf SF3B1-Mutationen, einschließlich von Next-Generation-Sequencing ... Test weist Mutationen des SF3B1-Gens nach, die ... günstigen Krankheitsverlauf vermuten lassen  QIAGEN ...
Breaking Medicine Technology:CPhI South America 2014 Launches with Generics Showing Huge Growth 2CPhI South America 2014 Launches with Generics Showing Huge Growth 3CPhI South America 2014 Launches with Generics Showing Huge Growth 4AcelRx Pharmaceuticals Confirms July 27, 2014 PDUFA Date for Zalviso 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 5
... Calif., Oct. 11 Threshold,Pharmaceuticals, Inc. (Nasdaq: THLD ... analysis, it would stop enrollment in a Phase 2 ... patients with,recurrent, sensitive small cell lung cancer. The ... there would be,an adequate response rate to justify complete ...
... KineMed Inc., a,pathway-based drug discovery and development company, ... an investigational agent,to regenerate nerve cells in the ... and mood. The agent, part of a partnered ... behavioral test in a,preclinical model. The findings were ...
Cached Medicine Technology:Threshold Pharmaceuticals to Stop Enrollment in Clinical Trial 2Threshold Pharmaceuticals to Stop Enrollment in Clinical Trial 3KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model 2KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model 3
(Date:7/25/2014)... CMS recently has imposed a series ... inadequate access to prescription drugs. Agency audits are uncovering ... safety of beneficiaries in areas such as rejected pharmacy ... is taking quick and firm actions to halt them. ... “Avoiding Costly Part D Sanctions: Rx Access Strategies ...
(Date:7/25/2014)... Wa (PRWEB) July 25, 2014 ... Pdf review recently updated by Vkool.com, this ... people how to treat some common types ... hemorrhoids and internal hemorrhoids ,     Young ... pregnancy with hemorrhoids ,     Very large ...
(Date:7/25/2014)... According to the Addict Him To You Pdf review ... that teaches women how to get the love of the ... review that this book consists of 4 parts, including:, ... commit yet (and what to do about it) , ... ,     Part 3: How to touch his heart deeply ...
(Date:7/25/2014)... Silver®Care , for the first time in ... that naturally kill oral bacteria and airborne bacteria from the ... toothbrush is the most common and important device in the ... is subject to constant contamination by bacteria found in the ... in the mouth than anywhere else in the human body, ...
(Date:7/24/2014)... July 25, 2014 iFitDress.com, a renowned ... new range of casual party dresses . According ... party gowns are now offered at discounted prices, up ... this morning until August 04. , Most of ... in the global market. They are popular for special ...
Breaking Medicine News(10 mins):Health News:Aug. 5 Webinar to Offer Strategies for Preventing Rx Access Issues and Avoiding Part D Sanctions 2Health News:Hemorrhoid No More Pdf Review Exposes Jessica Wright's Guide For Treating Hemorrhoids – Vkool.com 2Health News:Hemorrhoid No More Pdf Review Exposes Jessica Wright's Guide For Treating Hemorrhoids – Vkool.com 3Health News:Addict Him To You Pdf Review Exposes Mirabelle Summers' Dating Guide – Vkool.com 2Health News:Addict Him To You Pdf Review Exposes Mirabelle Summers' Dating Guide – Vkool.com 3Health News:Silver®Care’s New Silver Antibacterial Toothbrushes Naturally Kill Oral Germs 2Health News:Silver®Care’s New Silver Antibacterial Toothbrushes Naturally Kill Oral Germs 3Health News:2014 Casual Party Dresses for Chic Ladies Now at iFitDress.com 2
... Aug. 31 A new report,issued by the ... payments are 67 percent lower than anesthesia payments,from ... Anesthetists (CRNAs) are essential to ensuring that America,s ... pain management, and other,needed healthcare services., "Medicare ...
... of us hope our minds stay sharp,and active as ... simple as going to,the gym. Doctor Gary Small, a ... and aging, says the key to staying sharp is ... this report from Radica at:, http://media.medialink.com/WebNR.aspx?story=33787 Registered ...
... BlueCross BlueShield of South,Carolina has created a new ... Jill Davis to vice president in charge of ... to CEO M. Edward Sellers and is,responsible for ... formalizing a corporate-wide executive development program. "We ...
... Aug. 31 Lutheran Senior Services,(LSS), a leading ... that they provide the highest quality care and ... has partnered with Silverchair,Learning Systems to provide superior ... employees, beginning in January 2008. "Lutheran Senior ...
... Ill., Aug. 31 Landauer, Inc. (NYSE:,LDR) announced today ... dividend of $0.475 per share for the fourth quarter ... 5, 2007, to shareholders,of record on September 14, 2007. ... of analytical services to determine,occupational and environmental radiation exposure. ...
... World Heart,Corporation (WorldHeart) (Nasdaq: WHRT , ... today announced the appointment of,Mr. David Pellone as ... Juelis, the departing CFO, will provide consulting services,through ... the transition and with certain,specific projects. Mr. ...
Cached Medicine News:Health News:GAO Report Confirms: Medicare Underpays for Anesthesia Services; Nurse Anesthetists Assure Seniors Access to Safe Anesthesia Care 2Health News:S.C. BlueCross Creates Corporate Planning Unit, Promotes Davis to Vice President 2Health News:Lutheran Senior Services Partners with Silverchair Learning Systems to Enhance Employee Training and Education 2Health News:Lutheran Senior Services Partners with Silverchair Learning Systems to Enhance Employee Training and Education 3Health News:WorldHeart Appoints David Pellone Chief Financial Officer 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: